- Home
- SRL vs TCRX Comparison
SRL vs TCRX Comparison
Compare SRL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRL
- TCRX
- Stock Information
- Founded
- SRL 2017
- TCRX 2018
- Country
- SRL China
- TCRX United States
- Employees
- SRL N/A
- TCRX N/A
- Industry
- SRL Professional Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SRL Consumer Discretionary
- TCRX Health Care
- Exchange
- SRL Nasdaq
- TCRX Nasdaq
- Market Cap
- SRL 81.5M
- TCRX 91.7M
- IPO Year
- SRL N/A
- TCRX 2021
- Fundamental
- Price
- SRL $5.25
- TCRX $1.69
- Analyst Decision
- SRL
- TCRX Strong Buy
- Analyst Count
- SRL 0
- TCRX 5
- Target Price
- SRL N/A
- TCRX $9.40
- AVG Volume (30 Days)
- SRL 2.7K
- TCRX 215.6K
- Earning Date
- SRL 04-30-2025
- TCRX 11-11-2025
- Dividend Yield
- SRL 19.33%
- TCRX N/A
- EPS Growth
- SRL N/A
- TCRX N/A
- EPS
- SRL N/A
- TCRX N/A
- Revenue
- SRL $24,535,042.00
- TCRX $6,961,000.00
- Revenue This Year
- SRL N/A
- TCRX $255.18
- Revenue Next Year
- SRL N/A
- TCRX N/A
- P/E Ratio
- SRL N/A
- TCRX N/A
- Revenue Growth
- SRL N/A
- TCRX N/A
- 52 Week Low
- SRL $5.13
- TCRX $1.02
- 52 Week High
- SRL $9.99
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- SRL 44.87
- TCRX 41.04
- Support Level
- SRL $5.14
- TCRX $1.73
- Resistance Level
- SRL $5.50
- TCRX $1.96
- Average True Range (ATR)
- SRL 0.12
- TCRX 0.11
- MACD
- SRL 0.01
- TCRX -0.02
- Stochastic Oscillator
- SRL 20.37
- TCRX 10.00
About SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.